Our Vision
To build a future where the body’s natural healing abilities
are supercharged to improve the quality and length of life.
To battle and treat multiple inflammatory diseases and ailments through the use of stemXcell activated stem cell therapies.
stemXcell™︎ is the platform through which we discover, test and develop activated mesenchymal stem cells that are pre-programmed to treat targeted inflammatory diseases.
Today, we are preparing for FDA-authorized clinical trials that will test our stemXcell™︎ MSC treatments with enhanced immunomodulatory properties for treating chronic and acute liver diseases. Additionally, we are pursuing preclinical and clinical studies for other disease models, including NASH and ASH, and are continuing our research into numerous other inflammatory diseases.
2002
PrimeGen’s Story Begins!
- Starts cell therapy development using adult stem cells
2005
PrimeGen Expands Human Research and Development
- Focus expands to include immune-evasive MSCs
- Develops human adipose MSC platform
- Creates patented stem cell wound healing therapy
- Starts Parkinson’s Disease neural stem cell R&D
- Develops platform for making adult pluripotent stem cells
2006
PrimeGen Makes History
- Creates non-embryonic pluripotent stem cells (PSCs)
- Turned PSCs into beating cardiomyocytes
- Creates human heart, brain, bone and cartilage cells
- Partners with RTI to develop orthopedic cell therapies
2007
Sparks Legislators’ Interest in Cell Therapy
- Presents research at landmark Capitol Hill briefing
- Pioneers non-viral iPSC cell reprogramming
- Studies BMSCs ability to restore spinal cord function
2008
PrimeGen Creates Fertility Preservation Platform
- Creates platform to preserve cancer patient fertility
- Receives licensing approval from state of California for cell manufacturing facility
- Increases focus on treating inflammatory diseases
2012
PrimeGen Focuses on MSC Applications
- Begins allogenic MSC preclinical work for cirrhosis
- Commences research on human kidney applications
2014
Develops Veterinary Cell Therapy Models
- Starts MSC therapy development for pets
- Opens ISO-7 certified facility in California
2015
PrimeGen Introduces VetCell Therapeutics
- Launches VetCell brand to market therapies for pets
2017
Completes Human Cirrhosis Preclinical Study
- Concludes 5 year preclinical study of cirrhosis patients
- Embarks on FDA approval process for veterinary therapies
- FDA grants PrimeGen INADs for canine AD
- Starts clinical trial for treating canine OA with MSCs in Asia
- Initiates canine AD study with Western University
2018
PrimeGen Expands Global Presence
- FDA grants PrimeGen INAD for FCGS
- VetCell begins commercialization in Asia
2019
Prepares for Human Clinical Trials
- Prepares MSC clinical trial for liver cirrhosis in China
- Initiates preclinical liver MSC study with USC
- Initiates recruitment for FCGS clinical trial at UC Davis
2020
Entering Clinical Phases
- Initiates primed MSC clinical trial for liver cirrhosis in China
- Concludes human MSC liver study with USC
- Begins larger animal liver study with USC
- Expands integration of multimodal MSC treatments
- Initiates multi-center clinical trial for FCGS
2021
Gallant Acquires VetCell USA IP
- Gallant acquired VetCell FCGS IP
- PrimeGen sharpens focus on stemXcell platform
- PrimeGen expands clinical models for FDA review
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. PrimeGen US, Inc. makes no representation and assumes no responsibility for the accuracy of information contained on or available through this web site, and such information is subject to change without notice. You are encouraged to confirm any information obtained from or through this web site with other sources, and review all information regarding any medical condition or treatment with your physician.
NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BECAUSE OF SOMETHING YOU HAVE READ ON OR ACCESSED THROUGH ANY WEB SITE.